Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869218 · ClinicalTrials.gov registry record
Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 40
- Enrollment target
NCT01869218: Completed study, sponsored by University of Colorado, Denver.
NCT01869218 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01869218 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study is aimed to determine the feasibility of obtaining and molecularly characterizing pre-treatment tumor biopsies, to determine the feasibility of obtaining and molecularly characterizing archival and post-treatment tumor biopsies, to assess molecular expression changes between archival and baseline tumor samples, and to assess molecular expression changes between tumor samples obtained at baseline and at the time of disease progression.
Primary Outcome
As this is an exploratory, pilot feasibility study, data will be analyzed primarily with descriptive statistics. It is anticipated that this study will take up to 24-36 months to complete accrual of up to 50 patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-04-02 |
| Est. Completion | 2021-01-15 |
What the finished NCT01869218 record still lists
NCT01869218 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01869218 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01869218 about?
NCT01869218 is a clinical study titled "Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy". This study is aimed to determine the feasibility of obtaining and molecularly characterizing pre-treatment tumor biopsies, to determine the feasibility of obtaining and molecularly characterizing archival and post-treatment tumor biopsies, to assess molecular expression changes between archival and ...
What is the current status of trial NCT01869218?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2013-04-02. Estimated completion is 2021-01-15.
Who is sponsoring clinical trial NCT01869218?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI